Latest Breaking News On - Head of the hematology department - Page 1 : comparemela.com

Kuwait unveils plans for state-of-the-art new Cancer Control Center

Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024. In July 2023, ANVISA (Agência Nacional de Vigilância Sanitária) granted Market Authoriz

2023-10-16 | TSX:GUD | Press Release | Knight Therapeutics Inc

(2023-10-16 | TSX:GUD) Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Subcutaneous EPKINLY™ is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two or more lines.

EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Media Release Subcutaneous EPKINLYTM is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two.